{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:33:16Z","timestamp":1791844396690,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019871","name":"Castle Biosciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jaad.2022.06.1202","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T01:40:41Z","timestamp":1657244441000},"page":"1312-1320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Optimizing treatment approaches for patients with cutaneous melanoma by integrating clinical and pathologic features with the 31-gene expression profile test"],"prefix":"10.1016","volume":"87","author":[{"given":"Abel","family":"Jarell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian R.","family":"Gastman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry D.","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddy C.","family":"Hsueh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Podlipnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle R.","family":"Covington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine N.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann P.","family":"Quick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"Kurley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jaad.2022.06.1202_bib1","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"10.1016\/j.jaad.2022.06.1202_bib2","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/jnci\/djaa012","article-title":"Clinicopathological features, staging, and current approaches to treatment in high-risk resectable melanoma","volume":"112","author":"Keung","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.jaad.2022.06.1202_bib3","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2217\/fon-2018-0912","article-title":"Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling","volume":"15","author":"Vetto","year":"2019","journal-title":"Future Oncol"},{"issue":"9","key":"10.1016\/j.jaad.2022.06.1202_bib4","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1080\/03007995.2016.1192997","article-title":"Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients","volume":"32","author":"Berger","year":"2016","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1016\/j.jaad.2022.06.1202_bib5","first-page":"196","article-title":"Impact of gene expression profiling on decision-making in clinically node negative melanoma patients after surgical staging","volume":"17","author":"Schuitevoerder","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2022.06.1202_bib6","unstructured":"Swetter S.M., Thompson J.A., Coit D.G., et al. NCCN Practice Guildeines in Oncology. Cutaneous Melanoma. Version 3.2020, May 18, 2020."},{"issue":"4","key":"10.1016\/j.jaad.2022.06.1202_bib7","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/jid.2014.452","article-title":"More people die from thin melanomas (1 mm) than from thick melanomas (>4 mm) in Queensland, Australia","volume":"135","author":"Whiteman","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2022.06.1202_bib8","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa1310460","article-title":"Final trial report of sentinel-node biopsy versus nodal observation in melanoma","volume":"370","author":"Morton","year":"2014","journal-title":"N Engl J Med"},{"issue":"10336","key":"10.1016\/j.jaad.2022.06.1202_bib9","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jaad.2022.06.1202_bib10","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1002\/cam4.2128","article-title":"Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma","volume":"8","author":"Keller","year":"2019","journal-title":"Cancer Med"},{"issue":"6","key":"10.1016\/j.jaad.2022.06.1202_bib11","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.amjsurg.2021.03.028","article-title":"Utility of a 31-gene expression profile for predicting outcomes in patients with primary cutaneous melanoma referred for sentinel node biopsy","volume":"221","author":"Arnot","year":"2021","journal-title":"Am J Surg"},{"issue":"3","key":"10.1016\/j.jaad.2022.06.1202_bib12","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jaad.2020.03.053","article-title":"Molecular risk prediction in cutaneous melanoma: a meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients","volume":"83","author":"Greenhaw","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2022.06.1202_bib13","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13045-017-0520-1","article-title":"Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test","volume":"10","author":"Hsueh","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"15_suppl","key":"10.1016\/j.jaad.2022.06.1202_bib14","doi-asserted-by":"crossref","first-page":"9581","DOI":"10.1200\/JCO.2016.34.15_suppl.9581","article-title":"Performance of a 31-gene expression profile in a previously unreported cohort of 334 cutaneous melanoma patients","volume":"34","author":"Zager","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2022.06.1202_bib15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1158\/1078-0432.CCR-13-3316","article-title":"Development of a prognostic genetic signature to predict the metastatic risk\u00a0associated with cutaneous melanoma","volume":"21","author":"Gerami","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.jaad.2022.06.1202_bib16","doi-asserted-by":"crossref","first-page":"e720","DOI":"10.1016\/S1470-2045(18)30596-5","article-title":"Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?","volume":"19","author":"Grob","year":"2018","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.jaad.2022.06.1202_bib17","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/jamadermatol.2020.1730","article-title":"Consensus, controversy, and conversations about gene expression profiling in melanoma","volume":"156","author":"Chan","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2022.06.1202_bib18","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1200\/PO.21.00162","article-title":"Integrating 31-gene expression profiling with clinicopathologic features to optimize cutaneous melanoma sentinel lymph node metastasis prediction","volume":"5","author":"Whitman","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"17","key":"10.1016\/j.jaad.2022.06.1202_bib19","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.2217\/fon-2021-0996","article-title":"The 31-gene expression profile stratifies recurrence and metastasis risk in patients with cutaneous melanoma","volume":"36","author":"Jarell","year":"2021","journal-title":"Future Oncol"},{"issue":"5","key":"10.1016\/j.jaad.2022.06.1202_bib20","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/jdv.15454","article-title":"Early outcome of a 31-gene expression profile test in 86 AJCC stage IB-II melanoma patients. A prospective multicentre cohort study","volume":"33","author":"Podlipnik","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2022.06.1202_bib21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jaad.2018.07.028","article-title":"Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria","volume":"80","author":"Gastman","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2022.06.1202_bib22","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/PO.20.00119","article-title":"Long-term outcomes in a multicenter, prospective cohort evaluating the prognostic 31-gene expression profile for cutaneous melanoma","volume":"5","author":"Hsueh","year":"2021","journal-title":"JCO Precision Oncology"},{"issue":"12","key":"10.1016\/j.jaad.2022.06.1202_bib23","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1097\/DSS.0000000000001588","article-title":"Estimation of prognosis in invasive cutaneous melanoma: an independent study of the accuracy of a gene expression profile test","volume":"44","author":"Greenhaw","year":"2018","journal-title":"Dermatol Surg"},{"issue":"12","key":"10.1016\/j.jaad.2022.06.1202_bib24","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1002\/ijc.30407","article-title":"Epidemiology of cutaneous melanoma in Sweden\u2014stage-specific survival and rate of recurrence","volume":"139","author":"Rockberg","year":"2016","journal-title":"Int J Cancer"},{"issue":"11","key":"10.1016\/j.jaad.2022.06.1202_bib25","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1200\/JCO.20.02446","article-title":"Development and validation of nomograms to predict local, regional, and distant\u00a0recurrence in patients with thin (T1) melanomas","volume":"39","author":"El Sharouni","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jaad.2022.06.1202_bib26","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1245\/s10434-017-6325-1","article-title":"Long-term survival of patients with thin (T1) cutaneous melanomas: a Breslow thickness cut point of 0.8 mm separates higher-risk and lower-risk tumors","volume":"25","author":"Lo","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.jaad.2022.06.1202_bib27","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3832","article-title":"Initial stage of cutaneous primary melanoma plays a key role in the pattern and timing of disease recurrence","volume":"101","author":"Ertekin","year":"2021","journal-title":"Acta Derm Venereol"},{"issue":"20","key":"10.1016\/j.jaad.2022.06.1202_bib28","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.1158\/1078-0432.CCR-18-1311","article-title":"Bigger is not always better: tumor size and prognosis in advanced melanoma","volume":"24","author":"Warner","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"15_suppl","key":"10.1016\/j.jaad.2022.06.1202_bib29","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/jco.2014.32.15_suppl.3015","article-title":"Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475","volume":"32","author":"Joseph","year":"2014","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jaad.2022.06.1202_bib30","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1245\/s10434-020-08407-8","article-title":"Imaging intensity and survival outcomes in high-risk resected melanoma treated by systemic therapy at recurrence","volume":"27","author":"Ibrahim","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.jaad.2022.06.1202_bib31","first-page":"3591","article-title":"Nomogram for predicting the survival of patients with malignant melanoma: a population analysis","volume":"18","author":"Yang","year":"2019","journal-title":"Oncol Lett"},{"issue":"24","key":"10.1016\/j.jaad.2022.06.1202_bib32","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000016059","article-title":"A nomogram for predicting survival in patients with nodular melanoma: a population-based study","volume":"98","author":"Yang","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"10.1016\/j.jaad.2022.06.1202_bib33","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1245\/s10434-020-08959-9","article-title":"Sentinel node status is the most important prognostic information for clinical stage IIB and IIC melanoma patients","volume":"27","author":"Fonseca","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.jaad.2022.06.1202_bib34","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/bjs.10995","article-title":"Development and validation of a nomogram to predict recurrence and melanoma-specific mortality in patients with negative sentinel lymph nodes","volume":"106","author":"Verver","year":"2019","journal-title":"Br J Surg"},{"issue":"1","key":"10.1016\/j.jaad.2022.06.1202_bib35","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12885-018-4016-3","article-title":"Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients","volume":"18","author":"Zager","year":"2018","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.jaad.2022.06.1202_bib36","first-page":"239","article-title":"Establishing an evidence-based decision point for clinical use of the 31-gene expression profile test in cutaneous melanoma","volume":"3","author":"Marks","year":"2019","journal-title":"J Cutan Med"},{"issue":"4","key":"10.1016\/j.jaad.2022.06.1202_bib37","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1200\/PO.19.00206","article-title":"Model combining tumor molecular and clinicopathologic risk factors predicts sentinel lymph node metastasis in primary cutaneous melanoma","volume":"4","author":"Bellomo","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"9","key":"10.1016\/j.jaad.2022.06.1202_bib38","first-page":"3","article-title":"Risk stratication of patients with stage i cutaneous melanoma using 31-gene expression profiling","volume":"14","author":"Martin","year":"2021","journal-title":"J Clin Aesthet Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2022.06.1202_bib39","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/s41379-021-00870-2","article-title":"Histological regression in melanoma: impact on sentinel lymph node status and survival","volume":"34","author":"Aivazian","year":"2021","journal-title":"Mod Pathol"},{"issue":"8","key":"10.1016\/j.jaad.2022.06.1202_bib40","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1177\/000313481107700816","article-title":"Lymphovascular invasion as a prognostic factor in melanoma","volume":"77","author":"Egger","year":"2011","journal-title":"Am Surg"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222022538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222022538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:03:48Z","timestamp":1759273428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962222022538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0190962222022538"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2022.06.1202","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing treatment approaches for patients with cutaneous melanoma by integrating clinical and pathologic features with the 31-gene expression profile test","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2022.06.1202","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}